Accordingly, production of the endogenous antioxidant glutathione (GSH) by glial cells within the brain [8], particularly astrocytes [8,9,10], is a critical function, as most antioxidants are unable to cross the blood brain barrier
But then, in 2021, the FDA approved a formulation of semaglutide for weight loss (brand name Wegovy)
Semaglutide targets one specific hormone pathway, while tirzepatide is a dual-action drug targeting both GLP-1 and GIP receptors
Who should consider a medical evaluation before focusing on weight loss
These side effects are often mild, but they can be uncomfortable
And no studies have examined the effect of compounded semaglutide formulations, which may contain different excipients